Skip to content
Catalyst

PapersPMID:17898352

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

The American journal of psychiatry2007The record ↗

  1. Finding, very limited evidenceno difference foundScale for the Assessment of Negative Symptoms (SANS) total score

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “There were no significant differences in change in the SANS total score between glycine and placebo subjects or D-cycloserine and placebo subjects.”
    Study
    RCT
    Duration
    4 months
    Population
    Inpatients and outpatients with schizophrenia or schizoaffective disorder and moderate to severe negative symptoms, adjunctive glycine against placebo; the D-cycloserine arm is a separate comparison against the same placebo

Study record

Design
randomised controlled trial
Species
human
Population
inpatients and outpatients with schizophrenia or schizoaffective disorder and moderate to severe negative symptoms
Participants
157
Comparator
placebo
Duration
112 days
Endpoints measured
6
Declined
this platform holds no node for the endpoint